Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) — Market Cap & Net Worth
Market Cap & Net Worth: Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a market capitalization of $839.53 Million ($839.53 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9512 globally and #2630 in its home market, demonstrating a 0.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lexicon Pharmaceuticals Inc's stock price $2.31 by its total outstanding shares 444196390 (444.20 Million). See LXRX capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Lexicon Pharmaceuticals Inc Market Cap History: 2015 to 2026
Lexicon Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $5.91 Billion to $1.03 Billion (-13.67% CAGR).
Index Memberships
Lexicon Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.03% | #270 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1007 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.05% | #158 of 263 |
Weight: Lexicon Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lexicon Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lexicon Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.26x
Lexicon Pharmaceuticals Inc's market cap is 10.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.14 Billion | $83.34 Million | -$141.43 Million | 73.72x | N/A |
| 2017 | $4.39 Billion | $90.33 Million | -$129.05 Million | 48.58x | N/A |
| 2018 | $2.95 Billion | $63.21 Million | -$120.55 Million | 46.66x | N/A |
| 2019 | $1.84 Billion | $322.07 Million | $130.13 Million | 5.72x | 14.17x |
| 2020 | $1.52 Billion | $24.00 Million | -$58.57 Million | 63.31x | N/A |
| 2021 | $1.75 Billion | $298.00K | -$87.76 Million | 5872.93x | N/A |
| 2022 | $848.42 Million | $139.00K | -$101.94 Million | 6103.71x | N/A |
| 2023 | $679.62 Million | $1.20 Million | -$177.12 Million | 564.47x | N/A |
| 2024 | $328.04 Million | $31.08 Million | -$200.40 Million | 10.55x | N/A |
| 2025 | $510.83 Million | $49.80 Million | -$50.34 Million | 10.26x | N/A |
Competitor Companies of LXRX by Market Capitalization
Companies near Lexicon Pharmaceuticals Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Lexicon Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Lexicon Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Lexicon Pharmaceuticals Inc's market cap moved from $5.91 Billion to $ 1.03 Billion, with a yearly change of -13.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.03 Billion | +100.87% |
| 2025 | $510.83 Million | +55.72% |
| 2024 | $328.04 Million | -51.73% |
| 2023 | $679.62 Million | -19.90% |
| 2022 | $848.42 Million | -51.52% |
| 2021 | $1.75 Billion | +15.20% |
| 2020 | $1.52 Billion | -17.59% |
| 2019 | $1.84 Billion | -37.50% |
| 2018 | $2.95 Billion | -32.79% |
| 2017 | $4.39 Billion | -28.56% |
| 2016 | $6.14 Billion | +3.91% |
| 2015 | $5.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Lexicon Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $839.53 Million USD |
| MoneyControl | $839.53 Million USD |
| MarketWatch | $839.53 Million USD |
| marketcap.company | $839.53 Million USD |
| Reuters | $839.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more